CASI Stock Earnings: CASI Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024
CASI Pharmaceuticals Q2 2024 Results: CASI Pharmaceuticals reported a second-quarter earnings per share of -52 cents, surpassing the analyst estimate of -63 cents, but their revenue of $3.98 million fell short of the expected $4.43 million by 10.18%.
InvestorPlace Earnings Automation: InvestorPlace Earnings utilizes automated data from TradeSmith to provide timely coverage of quarterly earnings reports, highlighting key metrics like EPS and revenue against analyst estimates without human intervention.
Trade with 70% Backtested Accuracy
Analyst Views on CASI
About CASI
About the author
Dayforce Shares Surge Approximately 21%; Check Out 20 Stocks Making Moves in Premarket Trading
Dayforce Inc Acquisition Talks: Shares of Dayforce Inc rose 21.4% in pre-market trading following reports that Thoma Bravo is in discussions to acquire the company.
Notable Gainers: Other stocks experiencing significant gains include Propanc Biopharma (up 253%), Adaptimmune Therapeutics (up 70.3%), and DIH Holding US (up 43.4%).
Significant Losers: TPI Composites saw a drastic decline of 51.1%, while SRx Health Solutions and Empery Digital also faced notable drops of 25.8% and 22.2%, respectively.
Market Overview: The article highlights various stocks' movements in pre-market trading, showcasing both substantial gainers and losers, reflecting market volatility.
Premarket Stock Movements: PPCB, BTAI, TNXP, DAY, TPIC, and Other Notable Gainers and Losers
Premarket Trading Activity: Notable activity is observed in premarket trading as of 6.50 a.m. ET on Monday, indicating potential opportunities before the market opens.
Importance for Traders: Premarket trading allows active traders to identify possible breakouts, reversals, or price swings, making it crucial for analyzing momentum heading into the regular session.
Stocks Performance: Some stocks are showing significant percentage increases while others are experiencing notable declines during Monday's premarket session.
Author's Perspective: The views expressed in the article reflect the author's opinions and do not necessarily represent those of Nasdaq, Inc.
